<DOC>
	<DOCNO>NCT00002410</DOCNO>
	<brief_summary>The purpose study compare safety effectiveness three anti-HIV drug combination . The three combination : ( 1 ) efavirenz ( DMP 266 ) plus indinavir ; ( 2 ) DMP 266 plus zidovudine ( ZDV ) plus lamivudine ( 3TC ) ; ( 3 ) indinavir plus ZDV plus 3TC . This study also examine resistance HIV may drug drug effective long period time .</brief_summary>
	<brief_title>A Study Three Different Anti-HIV Drug Combinations HIV-Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<criteria>Exclusion Criteria Concurrent Medication : Excluded : Terfenadine , astemizole , cisapride , triazolam , midazolam ( competition enzyme cytochrome P450 3A4 [ CYP3A4 ] indinavir could result inhibition metabolic breakdown drug create potential serious and/or life threaten event [ i.e. , cardiac arrhythmia , prolonged sedation ] ) . Rifampin rifabutin ( prohibit potential drug interaction indinavir ) . Ketoconazole , itraconazole , clarithromycin . Concomitant systemic therapy acute opportunistic infection malignancy . Excluded : Life expectancy le 12 month . Prior Medication : Excluded : Prior treatment efavirenz , 3TC , NNRTI , HIV protease inhibitor . Prior antiretroviral agent within 14 day initiate study treatment . Prior treatment ( within 30 day initiate study treatment ) experimental drug indication . Patients must : Have diagnosis HIV infection . Have CD4 count great equal 50 cell/mm3 . Have life expectancy great equal 12 month . Be postpubescent .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 1998</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Drug Resistance , Microbial</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Indinavir</keyword>
	<keyword>Genotype</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>efavirenz</keyword>
</DOC>